New Optimer contract to develop bioanalytical tools for RNA therapy

Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease biopharmaceutical company.

Opinion | A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease

Brooks is a rare diseases researcher. Pritchett Clay is a researcher and chemist, and advocate for diversity in STEM. On Friday, the FDA approved two

December 12, 2023

Advanced deep learning technique enhances choroidal vessel visualization

Researchers from Peking University have developed a novel noninvasive choroidal angiography method that enables layer-wise visualization and evaluation of choroidal vessels using deep learning.

November 4, 2024

CAR T cells target senescent cells, improve healthspan in mice

Chimeric antigen receptor (CAR) T cells have transformed the treatment of blood cancers in recent years. And there have been positive signs the “living drugs”

February 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.